Back to Index
Kevin Kelly, MD
Associate Professor of Clinical Medicine
NOR 1441 Eastlake Ave Health Sciences Campus Los Angeles
+1 323 865 3828


Dr. Kelly is a hematologist with clinical expertise in phase I investigational therapeutics and hematological malignancies, including lymphoma and multiple myeloma. His research focuses on understanding the mechanisms of resistance to chemotherapy in hematological malignancies and the use of novel agents to overcome this resistance, and he has published extensively in peer-reviewed journals. Through collaborations with a large team of scientists, he has translated preclinical discoveries into novel clinical trials including an investigator-initiated study of the phosphodiesterase 4B inhibitor, roflumilast, in B cell lymphoproliferative disorders.

Dr. Kelly earned his medical degree and PhD from University College Cork. He then went on to complete an Advanced Drug Development Clinical Fellowship at The University of Texas Health Science Center.


National Cancer Institute: Cancer Clinical Investigator Team Leadership Award, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Travel Award, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Travel Award, 2009


Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations. Mod Pathol. 2016 Jun; 29(6):570-81. View in: PubMed

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan 1; 22(1):34-43. View in: PubMed

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget. 2015 Dec 1; 6(38):41275-89. View in: PubMed

The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine. Clin Cancer Res. 2015 Jan 15; 21(2):439-47. View in: PubMed

Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharmaceuticals (Basel). 2014; 8(1):1-20. View in: PubMed

Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res. 2013 Jul 1; 19(13):3577-90. View in: PubMed

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer. 2012 Dec 1; 131(11):2693-703. View in: PubMed

MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs. 2012 Oct; 21(10):1563-73. View in: PubMed

Autophagy as a target for cancer therapy: new developments. Cancer Manag Res. 2012; 4:357-65. View in: PubMed

Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br J Haematol. 2012 Jan; 156(1):129-32. View in: PubMed

Targeting aurora kinases in cancer treatment. Curr Drug Targets. 2011 Dec; 12(14):2067-78. View in: PubMed

The Pim kinases: new targets for drug development. Curr Drug Targets. 2011 Dec; 12(14):2059-66. View in: PubMed

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med. 2011 Oct; 15(10):2057-70. View in: PubMed

Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol. 2011 Mar; 6(1):17-27. View in: PubMed

Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol. 2011 Mar; 6(1):53-61. View in: PubMed

Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011 Feb 25; 286(8):6602-13. View in: PubMed

Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med. 2010 Oct; 14(10):2448-59. View in: PubMed

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 2010 May 6; 115(18):3796-800. View in: PubMed

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res. 2010 Jan 1; 16(1):141-53. View in: PubMed

Cdc7 kinase - a new target for drug development. Eur J Cancer. 2010 Jan; 46(1):33-40. View in: PubMed

Reovirus-based therapy for cancer. Expert Opin Biol Ther. 2009 Jul; 9(7):817-30. View in: PubMed

Emerging drugs in the treatment of pancreatic cancer. Expert Opin Emerg Drugs. 2009 Jun; 14(2):311-28. View in: PubMed

Powered bySC CTSI